

## Ranibizumab in Treatment for Age-related Macular Degeneration

Javier Araiz,<sup>1,2,3</sup> Luis Arias,<sup>3,4,5</sup> Alfredo García-Layana<sup>3,6</sup> and José María Ruiz-Moreno<sup>3,7,8</sup>

1. Department of Ophthalmology, University of the Basque Country Medical School, Bilbao; 2. Instituto Clínico Quirúrgico de Oftalmología (ICQO), Bilbao; 3. RETICS OFTARED (RD12/0034) 'Prevention, early detection and treatment of the prevalent degenerative and chronic ocular pathology' Institute of Health Carlos III, Madrid, Spain; 4. Department of Ophthalmology, Bellvitge University Hospital; 5. Associate Professor of Ophthalmology, University of Barcelona Medical School; 6. Department of Ophthalmology, Clínica Universidad de Navarra, University of Navarra Medical School, Pamplona; 7. Department of Ophthalmology, University of Castilla la Mancha Medical School, Albacete; 8. Visum Corporation, Alicante, Spain

**Citation:** *European Ophthalmic Review*, 2014;8(2)vii [online only]

**Erratum to:** *European Ophthalmic Review*, 2013;7(2):109–14

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following additions to the Disclosure section:

No funding was received in the publication of this article.